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Effects of depressive symptoms and peripheral DAT
methylation on neural reactivity to alcohol cues in alcoholism
CE Wiers1, E Shumay1, ND Volkow1,2, H Frieling3, A Kotsiari3, J Lindenmeyer4, H Walter5,6,7 and F Bermpohl5,6,7
In alcohol-dependent (AD) patients, alcohol cues induce strong activations in brain areas associated with alcohol craving and
relapse, such as the nucleus accumbens (NAc) and amygdala. However, little is known about the inﬂuence of depressive symptoms,
which are common in AD patients, on the brain’s reactivity to alcohol cues. The methylation state of the dopamine transporter gene
(DAT) has been associated with alcohol dependence, craving and depression, but its inﬂuence on neural alcohol cue reactivity has
not been tested. Here, we compared brain reactivity to alcohol cues in 38 AD patients and 17 healthy controls (HCs) using
functional magnetic resonance imaging and assessed the inﬂuence of depressive symptoms and peripheral DAT methylation in
these responses. We show that alcoholics with low Beck’s Depression Inventory scores (n= 29) had higher cue-induced reactivity
in NAc and amygdala than those with mild/moderate depression scores (n= 9), though subjective perception of craving was higher
in those with mild/moderate depression scores. We corroborated a higher DAT methylation in AD patients than HCs, and showed
higher DAT methylation in AD patients with mild/moderate than low depression scores. Within the AD cohort, higher methylation
predicted craving and, at trend level (P= 0.095), relapse 1 year after abstinence. Finally, we show that amygdala cue reactivity
correlated with craving and DAT methylation only in AD patients with low depression scores. These ﬁndings suggest that
depressive symptoms and DAT methylation are associated with alcohol craving and associated brain processes in alcohol
dependence, which may have important consequences for treatment. Moreover, peripheral DAT methylation may be a clinically
relevant biomarker in AD patients.
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INTRODUCTION
Alcohol dependence is a chronic relapsing disorder, characterized
by continued drinking despite an awareness of negative
consequences. People often start drinking because of the
rewarding, hedonic effects of alcohol, which are induced by
dopamine (DA) release in the nucleus accumbens (NAc).1,2 With
repeated exposure to alcohol, the cues associated with it (for
example, the sight of a bar or beer bottle) become conditioned
over the course of addiction. These cues, then, also lead to DA
increases in mesolimbic reward pathways, thereby acting as a
‘motivational magnet’ and triggering alcohol consumption.3
Indeed, neuroimaging studies have shown that alcohol cues
evoke strong responses in mesolimbic brain areas in alcohol-
dependent (AD) patients, including the NAc and amygdala, which
are associated with craving,4,5 and relapse after abstinence.6–8
Besides positive incentives, negative reinforcement motives,
such as the reduction of depressive symptoms or anxiety, also play
a key role in alcoholism, especially in later stages of the disease.9,10
Alcohol dependence and depression are highly comorbid11,12 and
alcoholism is often associated with dysphoria, that is, low mood,9
including blunted DA responses to natural rewards.2 DA projec-
tions from the ventral tegmental areas to the striatum have an
important role in both reward and mood,12 and it was recently
shown that AD patients exhibit impaired striatal reward
anticipation, which correlated negatively with depression
scores.13,14 However, little is known as to whether depressive
symptoms and/or positive and negative reinforcement motives of
craving are associated with alcohol cue reactivity, which is the ﬁrst
goal of the current study. We expected that mesolimbic cue
reactivity and positive reinforcement craving were especially
strong in patients with low depression scores, and that patients
with higher depression scores would predominantly report
negative reinforcement craving.
The DA transporter 1 (DAT) gene is implicated in both
substance dependence and depression and could contribute to
the comorbidity between these two disorders. For example, the
DAT1/SLC6A3 VNTR polymorphism modulates drug-induced cue
reactivity in the striatum in AD patients,15 striatal DAT availability
and the severity of alcohol withdrawal.16 As the DAT1 9 R allele
has been associated with reduced DAT expression,17 it may be
that the allele leads to accumulation of synaptic DA, which results
in increased reward processing. Lower striatal DAT availability has
also been reported in patients with major depressive disorder,18,19
possibly in response to reductions in DA neurotransmission.
The expression of DAT is also affected by the methylation state
of the DAT promoter area. Preclinical studies demonstrate that
elevated DAT methylation is related to reduced expression of
DAT protein in the rat cortex and striatum.20 Although there is
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currently no evidence for this relationship in humans, it has been
shown that DAT methylation of peripheral blood cells is elevated
in AD patients compared with controls21 and negatively associated
with craving.21,22 Therefore, the second goal of this study was to
investigate the relationships between the DAT promoter methylation
state of peripheral blood cells (from now on: ‘DAT methylation’),
alcohol cue reactivity and its interaction with depressive symptoms.
Moreover, we explored whether DAT methylation could predict
alcohol craving, and relapse 1 year after abstinence.
To accomplish this, we studied 38 recently detoxiﬁed male AD
patients and 17 healthy controls (HCs) on an alcohol cue reactivity
task in a 3-Tesla magnetic resonance imaging scanner. Peripheral
blood measures were taken to assess DAT methylation state. We
aimed to replicate the initial ﬁnding that the DAT promoter
methylation state in blood is elevated in AD patients compared
with HCs, and that the degree of DAT methylation covaries with
alcohol craving.21,22 In addition, we hypothesized that if DAT
methylation affects its expression and if peripheral DAT methyla-
tion is reﬂective of DAT methylation in the brain, then elevated
peripheral DAT methylation will be associated with stronger
alcohol cue-induced blood oxygenation level dependent
responses in mesolimbic brain areas (that is, NAc and amygdala),
and could predict alcohol relapse. Given previous ﬁndings of
reduced DAT availability in depression,18,19 we also expected
elevated peripheral DAT methylation in AD patients with higher
depression scores and greater negative reinforcement craving.
MATERIALS AND METHODS
Participants and questionnaires
The Ethical Committee of the Charité Universitätsmedizin Berlin approved
the study and a total of 38 AD inpatients and 17 HCs matched for age,
years of education, intelligence (WAIS matrices)23 and body mass index
(P40.09) were included. All the participants were Caucasian males. The
patients were recruited from an inpatient clinic and controls were recruited
via online advertisements. All the participants gave written informed
consent before the study.
Exclusion criteria for all the participants were a history of neurological
dysfunctions, axis I psychiatric disorders according to DSM-IV criteria other
than alcohol (in the AD group) and nicotine dependence (M.I.N.I. plus, an
International Neuropsychiatric Interview).24 None of the participants met
criteria for major depressive disorder according to DSM-IV. For controls,
potential participants with scores above 8 on the Alcohol Use Disorder
Identiﬁcation Test25 were excluded, as determined in a telephone
interview before participation. The patients were recently detoxiﬁed
(o6 months, minimum of 1 week) and had been suffering from alcohol
dependence for 15.29 ± 8.25 years (see Table 1). Smokers were abstinent
from tobacco at least 1.5 h before scanning.
We assessed lifetime alcohol intake in both the groups by means of the
Lifetime Drinking History (LDH),26 and, in the patient group only, severity
of dependence with the Alcohol Dependence Scale (ADS).27 Both groups
rated their alcohol craving on the 14-item version of the Desire for Alcohol
Questionnaire (DAQ),28 which can be divided into three components:
positive reinforcement/desire to drink (for example, ‘Drinking would be
satisfying now’), negative reinforcement (for example, ‘Drinking now would
make me feel less tense’) and ability to control drinking (for example, ‘If I
started drinking now I would be able to stop’). Depressive symptoms were
measured using the Beck’s Depression Inventory (BDI), a 21-question
multiple-choice self-report inventory.29
Assessment of DAT promoter methylation
Fasting ethylenediaminetetraacetic acid blood samples were taken directly
after scanning sessions and were stored at − 80 °C after collection.
Automated isolation of genomic DNA from whole blood was carried out
by the magnetic-bead-based NucleoMag Blood 200 μl Kit (Macherey Nagel,
Düren, Germany). After bisulﬁte treatment of the DNA (EpiTect 96 Bisulﬁte
Kit, Qiagen, Hilden, Germany), the DAT promoter (from − 1037 to − 701)
was ampliﬁed by PCR using the following primers: 5′-TTGTAGGTT
GGAATGGTTG-3′ (forward) and 5′-CCTAAAAAAACCATTTCCC-3′ (reverse,
annealing temperature 56 °C, product length 336 bp). Ampliﬁcation
product of PCR was puriﬁed using Agencourt AMPure XP PCR Puriﬁcation
Kit (Beckman Coulter, Krefeld, Germany). Sequencing was performed to
measure the methylation state of 12 CpG sites residing within the DAT
promoter (from − 1037 to − 829; sequencing primer 5′-AAAAAATAAAACC
CCC-3′, product length 208 bp) using the BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA, USA). Sequencing
reaction was puriﬁed by Agencourt CleanSEQ Dye-Terminator Removal Kit
(Beckman Coulter) before analysis with the Applied Biosystems 3500xL
DNA Genetic Analyzer (Applied Biosystems). The methylation rate of each
CpG site was determined using the Epigenetic Sequencing Methylation
Analysis software.
Functional magnetic resonance imaging cue reactivity task,
acquisition and preprocessing
A total of 80 cues (40 alcohol, 40 soft drink) were presented over 16 blocks
(8 alcohol blocks, 8 soft-drink blocks). Per block, ﬁve cues were presented
Table 1. Demographic and clinical characteristics of AD patients and HCs
Characteristic Alcohol-dependent patients,
N= 38
Healthy controls, N= 17 P-value
Mean s.d. Mean s.d.
Age, years 44.39 7.32 42.71 9.15 0.47
Years of education 10.45 1.24 11.12 1.69 0.16a
WAIS, matrix reasoning 14.91b 4.93 17.59 5.48 0.10a
BMI 26.04c 4.56 24.38 2.26 0.16d
Packyears 17.86c 15.20 8.71 14.19 0.018a
LDH 1405.27e 1319.10 144.59 221.90 0.000a
Duration of dependence, years 15.29 8.25 — — —
Length of abstinence, days 52.63 42.77 — — —
Alcohol Dependence Scale 15.70e 7.47 — — —
DAQ sum 14.27e 7.28 4.88 4.43 0.000
DAQ positive reinforcement 3.24e 3.94 2.88 2.80 0.74
DAQ negative reinforcement 4.38e 3.79 1.71 1.79 0.013a
DAQ control 6.65e 1.87 0.29 0.59 0.000a
BDI 6.05 5.82 5.46f 5.07 0.93a
Abbreviations: AD, alcohol-dependent; BDI, Beck’s Depression Inventory Scale; BMI, body mass index; DAQ, Desire for Alcohol Questionnaire; HC, healthy
control; LDH, Lifetime Drinking History; WAIS, Wechsler Adult Intelligence Scale. aMann–Whitney U-test statistics, as sample(s) are not normally distributed.
bN= 35. cN= 36. dWelch’s t-test was used since equality of variance was not assumed (Levene’s test Po0.05). eN= 37. fN= 11. P-values in bold are o0.05.
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for 4 s each. Four ‘oddball’ blocks were added in which participants had to
press a button with their right index ﬁnger when they would see an
‘oddball’, deﬁned as being a picture of an animal. Oddball blocks were
removed from the analysis and the cue reactivity contrast of interest was
(alcohol blocks4soft drink blocks). Task duration was 6min. Cue reactivity
task speciﬁcs and data of a subsample of 30 AD patients have been
reported earlier.5
Scanning was performed in a 3-Tesla whole-body magnetic resonance
imaging scanner (Magnetom Trio Tim, Siemens, Germany) with a 12-
channel head coil. A standard T2-weighted echo planar imaging sequence
was used with the following parameters: sequential descending acquisi-
tion, 2 s repetition time, 25ms echo time, 80° ﬂip angle, 64 × 64 pixels in-
plane resolution, 34 slices, 3 mm slice thickness, voxels were 3 × 3× 3mm3,
0.75-mm gap between slides, 192 × 192mm2 ﬁeld of view, and 140 images
per session. Functional data analysis was performed with SPM8. Scans were
spatially realigned, slice-time corrected and normalized to the standard
echo planar imaging template. Smoothing was performed with an 8-mm
full-width at half maximum Gaussian kernel. Participants did not move
more than 3 mm or 3 degrees per block, and hence none of the
participants were excluded on the basis of this criterion.
Statistical analyses
Craving and depression scores. DAQ craving scores were normally
distributed in both the groups, whereas BDI scores in the AD group were
not (Kolmogorov–Smirnov test, P= 0.011). The AD patient group was split
into two depressive symptom subgroups according to the BDI cut-off
scores proposed by Beck et al.:29 0–9 indicating minimal depression (n=29;
mean= 3.23 ± 2.63), 10–19 indicating mild depression and 419 indicating
moderate depression (mild and moderate together: n= 9,
mean= 14.94 ± 3.98).29 BDI data of six HCs were missing. None of the
participants had BDI scores indicative of severe depression (⩾30). DAQ
craving scores in the minimal and mild/moderate depression group were
also normally distributed (Kolmogorov–Smirnov test P40.20).
DAT methylation. The DAT promoter methylation state of DNA isolated
from ethylenediaminetetraacetic acid whole blood was calculated as the
mean percentage of methylation of 12 CpG sites. Mean DAT methylation
was normally distributed according to the Kolmogorov–Smirnov test in
each diagnostic group (P40.72) and in the two patient groups on the basis
of depression sores (P40.20). Despite a previous study that found that
DAT methylation and age were positively correlated,22 in the current
sample we did not ﬁnd age and DAT methylation to be correlated within
each group (P40.38) or within both groups combined (P= 0.48). Moreover,
smoking packyears (that is, (cigarettes per day/20× smoking duration)) did
not correlate with methylation in either group (P40.54). Therefore, we did
not add age or packyears as covariates to our analyses.
Neural alcohol cue reactivity. Three functional magnetic resonance
imaging regressors (alcohol, soft drink and oddball blocks; 20 s each)
were built for every subject and were convolved with the hemodynamic
response function with default temporal ﬁltering of 128 s. On the single
subject level, the contrast difference (alcohol blocks 4soft drink blocks)
was calculated. We used anatomically deﬁned bilateral amygdala and
ventral striatum as our regions of interest (ROIs) using the human
anatomical WFU Pickatlas.30 These two ROIs were also used in our previous
alcohol studies.5,31
Group comparisons and correlations. Mean beta values from all voxels in
each ROI were extracted using MarsBaR software for SPM8 (MARSeille Boîte
À Région d’Intérêt; http://marsbar.sourceforge.net), which provided an
estimate of alcohol cue reactivity in each ROI. These measures were
compared between groups using independent t-tests (Student’s t-test, or
Welch’s t-test if Levene’s test for equality of variance was Po0.05) and
correlated (Pearson’s r, two-tailed) with craving scores (including
exploratory correlations with craving subscores) and DAT methylation
state, with a signiﬁcance threshold of Po0.05 using SPSS 22 (IBM, Armonk,
NY, USA). For variables that were not normally distributed, we used the
Mann–Whitney U-test for group comparisons and Spearman’s rank-order
rho for correlation analyses. We corrected for the number of ROIs used and
report both corrected and uncorrected P-values. Results with P-values of
0.05oPo0.1 are reported as trends. Exploratory whole-brain analyses in
AD patients versus HCs and AD patients with low versus mild/moderate
depression scores were calculated within SPM8, with a threshold of
Po0.001 uncorrected and cluster size of k420.
Relapse after abstinence
One year after abstinence, alcohol relapse rates of AD patients were
acquired through postal and telephone interviews.5 Relapse was deﬁned
as drinking alcohol within the last 12 months for at least 3 days in a row. A
single lapse shorter than 3 days that was ended by the patient without
further negative consequences was still considered abstinence, which is in
line with previous measures of relapse.32,33 Measures of craving, neural
alcohol cue reactivity and DAT methylation were compared between
patients who abstained or relapsed abstainers within 1 year, using
independent t-tests in SPSS with the thresholds described above.
RESULTS
Subject characteristics and behavioral craving
AD patients versus HCs. Table 1 lists clinical and demographic
data of AD patients and HCs including mean± s.d. and P-values of
group statistics, showing that groups did not differ in age,
education or intelligence scores. AD patients reported stronger
alcohol craving (DAQ sum score) compared with HCs (Student’s
t52 = 4.90, Po0.0001). This effect was owing to stronger craving
on the negative reinforcement (Mann–Whitney U= 185.5,
P= 0.013) and ability to control drinking (U= 10.5, Po0.001)
subscales. There were more smokers in the AD group (30/38) than
in the HC group (6/17) (χ2 = 9.90, P= 0.002).
AD patients; low depression versus mild/moderate depression
scores. Clinical and demographic data for the two subgroups of
AD patients on the basis of severity of depressive symptoms
according to BDI are reported in Table 2. The groups did not differ
in age, education, intelligence, body mass index, lifetime alcohol
intake or smoking characteristics (all P40.05). Patients with mild/
moderate depression scores, however, had higher scores on the
ADS (t35 = 2.20, P= 0.035) and a longer history of dependence
(t36 = 2.15, P= 0.038) than patients with low BDI scores. Moreover,
patients with mild/moderate depression scores reported signiﬁ-
cantly stronger total DAQ craving (t35 = 2.31, P= 0.027) compared
with patients with low depression scores, particularly for the
negative reinforcement subscale (t35 = 2.22, P= 0.033). There were
no group differences for the subscale positive reinforcement or
ability to control. Despite a strong comorbidity between smoking
and depression,11 there were more smokers in the low depressed
(25/29) than mild/moderate depressed (5/9) group (χ2 = 3.88,
P= 0.049), but no between-group differences in cigarette pack-
years (P= 0.18; see Table 2).
DAT methylation
AD patients versus HC. DAT promoter methylation state was
elevated in AD patients (mean= 15.30 ± 5.14% s.d.) compared with
HCs (mean= 12.13 ± 3.24%; Welch’s t46.7 = 2.76, P= 0.008;
Figure 1a), and predicted DAQ craving in AD patients (r2 = 0.14,
P= 0.024), but not in HCs (r2 = 0.043, P= 0.427). When comparing
regression slopes between groups, the AD group showed a
stronger correlation between DAT methylation and DAQ craving
than HCs (Fisher’s z= 1.88, P= 0.03; Figure 1b). The regression
between DAT methylation and craving in AD patients was
particularly apparent for the negative reinforcement subscale
(r2 = 0.172, P= 0.011), but did not reach signiﬁcance for the two
other subscales (control and positive reinforcement P40.22).
AD patients; low depression versus mild/moderate depression
scores. Patients with mild/moderate depression scores had
elevated levels of DAT methylation (mean= 18.98 ± 4.17%) com-
pared with AD patients with low BDI scores (mean= 14.16 ± 4.93%;
t36 = 2.65, P= 0.012). Although DAT methylation predicted DAQ
craving in AD patients pooled together, the regression did not
reach signiﬁcance for the AD subgroups on the basis of BDI score
(P40.17).
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Neural alcohol cue reactivity
All the participants responded to all four ‘oddballs’, and hence
paid attention to the cue reactivity task.
AD patients versus HC. There were no group differences between
AD patients and HCs for alcohol cue-induced reactivity in our ROIs.
Moreover, an exploratory whole-brain analysis using a liberal
threshold of alpha Po0.001 and uncorrected k420 did not show
group differences. Activations in both ROIs did not correlate with
craving or methylation state in either group (P40.05).
AD patients; low depression versus mild/moderate depression
scores. AD patients with low depression scores had elevated
alcohol cue-induced reactivity in the NAc (t36 = 2.06, uncorrected
P= 0.046, corrected P-value for two ROIs = 0.092) and amygdala
(t36 = 2.71, uncorrected P= 0.010, corrected P= .020) when
compared with AD patients with mild/moderate depression
(When correcting group comparisons for potential confounding
factors—that is, smoking status, duration of dependence, ADS
scores and DAQ craving; see Table 2; group differences in NAc
(t= 2.50, uncorrected P= 0.018, corrected P= 0.036) and amygdala
(t= 2.74, uncorrected P= 0.010, corrected P= 0.020) remained.)
(Figure 2). An exploratory whole-brain analysis using a liberal
threshold of alpha Po0.001 and uncorrected k420 revealed
increased alcohol cue reactivity for AD patients with low versus
mild/moderate severity in medial prefrontal cortex (peak Montreal
Neurological Institute [x,y,z] = [− 6,44,− 8], Po0.001 family-wise
error cluster-corrected), bilateral thalamus (peak right = [6,− 7,− 2],
Po0.001 uncorrected), left putamen/insula (peak = [− 27,14,− 8],
P= 0.027 family-wise error cluster-corrected) and right brainstem
(peak = [3,− 31,− 38], P= 0.038 family-wise error cluster-corrected;
see Supplementary Table S1).
Figure 1. (a) Mean peripheral DAT promoter methylation in AD patients and HCs (mean%± s.d.). AD patients had elevated DAT methylation
compared with HCs (P= 0.008). (b) DAT methylation predicted DAQ craving in AD patients (r2= 0.14, P= 0.024), whereas not in HCs (r2= 0.043,
P= 0.43). When comparing regression slopes between these groups, the AD group showed a stronger correlation between DAT methylation
and DAQ craving than HCs (Fisher’s z= 1.88, P= 0.03). AD, alcohol-dependent; DAQ, Desire for Alcohol Questionnaire; DAT, dopamine
transporter gene; HC, healthy control.
Table 2. Demographic and clinical characteristics of AD patients with low (BDI o10) and mild/moderate depression scores (BDI 410)
Characteristic Alcohol-dependent patients, low





Mean s.d. Mean s.d.
Age, years 44.45 7.37 44.22 7.60 0.95a
Years of education 10.48 1.35 10.33 1.00 0.81a
WAIS, matrix reasoning 14.69b 4.96 15.56 5.05 0.66
BMI 25.90c 4.42 26.55d 5.31 0.73
Packyears 19.64e 14.89 12.53 15.76 0.18a
LDH 1207.72 1126.27 2121.39d 1768.32 0.22a
Duration of dependence, years 13.76 7.94 20.22 7.65 0.038
Length of abstinence, days 56.83 44.10 39.11 37.21 0.17a
Alcohol Dependence Scale 14.25c 6.57 20.22 8.66 0.035
DAQ sum 12.90 5.93 19.25d 9.79 0.027
DAQ positive reinforcement 2.79 3.22 4.88d 5.87 0.19
DAQ negative reinforcement 3.69 3.36 6.88d 4.42 0.033
DAQ control 6.41 1.99 7.50d 1.07 0.15a
BDI 3.29 2.63 14.94 3.97 0.000a
Abbreviations: AD, alcohol-dependent; BDI, Beck’s Depression Inventory Scale; BMI, body mass index; DAQ, Desire for Alcohol Questionnaire; LDH, Lifetime
Drinking History; WAIS, Wechsler Adult Intelligence Scale. aMann–Whitney U-test statistics, as sample(s) are not normally distributed. bN= 26. cN= 28. dN= 8.
eN= 27. P-values in bold are o0.05.
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Only in AD patients with low depression scores, alcohol cue
reactivity in the amygdala correlated positively with DAQ craving
(DAQ sum: r= 0.48, P= 0.008) and with DAT methylation (r= 0.42,
P= 0.022). The correlation with craving was apparent for the DAQ
subscales positive reinforcement (r= 0.37, P= 0.049) and negative
reinforcement (r= 0.47 P= 0.010), but not for ability to control
drinking (P= 0.90). Activation in the NAc did not correlate with
craving in any group (P40.13), despite a trending correlation
between craving and NAc activation that we found in a subset of
30 AD patients reported earlier.5 Further, amygdala and NAc
reactivity did not correlate with other clinical variables, including
years of alcohol dependence, LDH, ADS or smoking packyears in
any group (all P40.1).
Relapse prediction
A total of 29 AD patients responded by either mail or phone. Of
these, 17 remained abstinent, whereas 12 relapsed within a year
after abstinence. Although craving scores and alcohol cue
reactivity did not differ between groups (P40.05), DAT methyla-
tion tended to be higher in patients who relapsed (17.24 ± 5.08% s.
d.) than those who abstained (14.07 ± 4.50% s.d.) at trend level
(t27 = 1.73, P= 0.095; see Figure 3). The two BDI groups did not
differ in relapse (low depression group: 14 abstained and 10
relapsed; mild/moderate depression group: three abstained and
two relapsed; χ2 = 0.005, P= 0.95). However, DAT methylation
predicted relapse as a trend in AD patients with low BDI scores
(t22 = 2.07, P= 0.051), whereas not in patients with mild/moderate






















Figure 2. AD patients with low depression scores had stronger alcohol cue reactivity in the bilateral NAc (P= 0.046; a) and bilateral amygdala
(P= 0.01; b) compared with AD patients with moderate/high depression scores. Regions of interest were anatomically deﬁned. There were no
group differences between AD patients (both groups pooled together, n= 38) and HCs (n= 17) for alcohol cue-induced reactivity. AD, alcohol-
dependent; HC, healthy control; NAc, nucleus accumbens.
Figure 3. DAQ craving correlated with neural alcohol cue reactivity
in the bilateral amygdala in the AD group with low depression
(depr) scores (r= 0.48, P= 0.008), but not in the group with mild/
moderate depression scores (P40.1). AD, alcohol-dependent; DAQ,
Desire for Alcohol Questionnaire.
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depression scores (U= 3, P= 1; but please note that the sample
size was only ﬁve in this group). Supplementary Table S2 lists
the clinical and demographic characteristics of relapsers and
abstainers.
DISCUSSION
The main ﬁnding of this study is that depression scores, as
measured through the BDI, have impact on neural alcohol cue
reactivity in AD patients without a comorbid diagnosis of major
depression. Speciﬁcally, we found that in alcoholics, cue reactivity
in the bilateral amygdala, NAc (at trend level when corrected for
multiple comparisons), as well as other areas in the brain reward
circuitry (for example, medial prefrontal cortex, thalamus, puta-
men, insula), was stronger in AD patients with low BDI scores
compared with those with mild/moderate depression scores.
Therefore, this indicates that AD patients with higher depression
scores not only show reduced striatal reactivity to general reward
processes,13 but also less alcohol-speciﬁc mesolimbic reward
reactivity. Enhanced reactivity to drug cues in alcohol and drug
abusers is thought to be a core mechanism underlying cue-
induced craving, relapse and treatment success,4,8,10 which may
persist even after alcohol abstinence.3 However, the results of our
study suggest heterogeneity in mesolimbic cue reactivity and
craving: we found that patients with higher depression scores
failed to show increases in brain reward areas for alcohol cues,
which may have consequences for treatment. For example,
alcohol cue exposure therapies may be successful only in
individuals with low depressive symptoms.
On a behavioral level, a reverse pattern was shown for craving
ratings: patients with mild/moderate depression scores reported
stronger DAQ craving than low-depressed patients, which, in line
with our hypothesis, was particularly apparent for the negative,
but not for the positive reinforcement, subscale. This suggests that
negative reinforcement craving is predominant in patients with
higher depression scores, and, indeed, it has been proposed that
these patients try to reduce dysphoria with alcohol.9,11,34 Although
patients with higher BDI scores also scored higher on the ADS and
were generally dependent for a longer period of time which may
have inﬂuenced the results, these variables were not associated
with brain cue reactivity over the whole patient population, or
within the subgroups. In fact, when correcting group comparisons
for these potential confounding factors (that is, smoking status,
duration of dependence, ADS scores and DAQ craving), the
differences in cue reactivity were even stronger. Only in AD
patients with low depression scores, alcohol cue reactivity in the
amygdala correlated with alcohol craving (both sum, positive and
negative reinforcement), whereas no associations were found in
the group with higher depression scores. This further suggests
that a subgroup of AD patients with higher depression scores do
not show mesolimbic cue reactivity and have increased negative
reinforcement craving. The association between amygdala cue
reactivity and craving was previously found in a subsample 30 AD
patients,5 although that study did not explore depressive
symptoms.
Another important ﬁnding of the study is that the methylation
state of the DAT promoter measured in peripheral blood cells was
associated with alcoholism, craving processes and as a trend for
relapse (P= 0.095). This is consistent with an earlier ﬁnding that
peripheral DAT methylation was elevated in AD versus HC21 and
that it predicted alcohol craving.21,22 Although these previous
studies found a reverse correlation between DAT methylation and
craving, in our study we observed a positive association,
particularly for the negative reinforcement subscale. This differ-
ence may be due to different scales used: the previous studies
used the Obsessive Compulsive Drinking Scale, which distin-
guishes the three factors obsession, interference and control
impairment, but does not assess negative reinforcements.35 This
may also explain why the subgroup with higher depression scores
demonstrated higher DAT methylation. A preliminary ﬁnding from
our study was that DAT methylation showed a trend for being
higher in relapsing versus abstaining AD patients, as assessed 1
year after detoxiﬁcation. Thus, further research on the value of
DAT methylation in peripheral blood as a potential biomarker for
alcoholism and its value in predicting clinical outcomes merits
investigation.36
We did not ﬁnd evidence in support of our hypothesis on a
direct association between alcohol cue reactivity and DAT
methylation in all the AD patients. However, after splitting the
AD patients into depression groups, we found that in AD patients
with low depression scores alcohol cue reactivity in the amygdala
(but not the NAc) correlated with DAT methylation and craving
(see above). The lack of a correlation in the group consisting of
patients with higher depressive symptoms may have been owing
to the small sample size.
Previous studies in AD have focused on DAT availability in the
striatum16,37 and involvement of the DAT1 9 R allele in striatal cue
reactivity,15 but did not report results on the amygdala. Similarly,
lower striatal DAT availability has been found in the striatum of
depressed individuals.18,19 Recently, however, the DAT1 9 R allele
has been implicated in amygdala reactivity to salient cues.38 In an
animal model of alcoholism, Jiao et al.39 found that chronic
alcohol use increased DAT binding in the amygdala and substantia
nigra in depressive-like and non-depressive-like rat strains, but
only in the NAc of depressed rats. It is possible that the differences
between the strains in alcohol-induced DAT binding are, at least,
in part, due to genetic make-up, which, in turn, determines
dopaminergic differences in reward and depression. These
studies, together with our ﬁndings, corroborate the importance
of the amygdala in alcohol dependence and its interaction with
depressive symptoms and DAT. Although both DAT promoter
methylation and the DAT VNTR polymorphism have been shown
to alter DAT expression, it is not clear whether these alterations
are inter-related. The DAT methylation region analyzed in our
study is in the extended promoter region of the DAT1 gene,
whereas the VNTR polymorphism resides in the 3′-UTR. To the
best of our knowledge, it is not known whether the length of the
3′-UTR polymorphism inﬂuences the methylation proﬁle of the
promoter, which should be subject of future studies. Moreover, it
remains unclear how DAT promoter methylation in the peripheral
tissue relates to DAT expression and function in the brain.
Our study has some important limitations. First, AD patients
were recently detoxiﬁed treatment-seeking inpatients and, there-
fore, the severity of depression (that is, the BDI assesses symptoms
in the past 2 weeks) may have been directly associated with the
severity of withdrawal symptoms that the patients were
experiencing,34 which we did not assess. Second, we excluded
AD patients with comorbid axis I psychiatric disorders (other than
nicotine dependence), including depression and anxiety, which
reduces the generalizability of the study to the general AD
population who frequently show comorbid illnesses. However, our
goal was to study the brain reward circuitry in alcohol
dependence without a potential confounding factor of general
anhedonia owing to a primary depressive disorder.40 A previous
study in AD patients with comorbid depressive and anxiety
disorders found that depression scores correlated with alcohol
cue-induced reactivity in the precuneus and parietal lobe, but not
in the mesolimbic areas in the AD patients.41 A likely reason for
the differences between the ﬁndings of Sjoerds et al.41 and our
study is their merging of patients with these comorbid diagnoses.
Indeed, the scale used by Sjoerds et al. indicated depression
scores above clinical threshold (in some of the AD population),
whereas none of the patients in the current cohort had BDI scores
indicating clinical levels of severe depression. A third limitation is
that there were missing values in the HC group, which made it
difﬁcult to make strong conclusions about whether depression
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scores inﬂuenced alcohol cue reactivity in this group. Future
research using a 2 × 2 factorial design with AD patients/HCs, with
low/moderate depression scores may reveal whether DAT
methylation is also elevated in HCs with BDI scores indicating
moderate depression. Fourth, DAT methylation was measured in
the peripheral blood cells and it is currently unclear whether
methylation of this promoter region in blood is an accurate
representation of the methylation state in brain tissue. Compar-
isons between epigenetic marks of DAT in peripheral tissue and
the brain, either postmortem or in vivo using imaging techniques,
are hence needed. Recent studies investigating blood and brain
relationships found mixed results: some studies report strong
correlations between the methylation state of brain and blood
tissues,42–44 whereas others emphasize differences between these
tissues,45,46 especially in genes involved in cell differentiation.46,47
Interestingly, it has been suggested that methylation in saliva
rather than blood may be a better marker for brain
methylation.47,48 Last, our AD patients and HC group also differed
in smoking behavior, which may have confounded the results.
Also, the BDI cut-off scores of 10 made the group of AD patients
with mild/moderate depression scores rather small and the
ﬁndings, therefore, have to be replicated in larger samples.
In summary, we believe our study is the ﬁrst to demonstrate
reduced mesolimbic cue reactivity in alcoholic patients with
higher depression scores. Moreover, peripheral DAT promoter
methylation state may merit further investigation as a potential
biomarker in AD patients as it (1) was greater in AD patients versus
HCs, (2) was a predictor of alcohol craving in AD patients, (3)
showed a trend towards predicting relapse 1 year after abstinence
and (4) was associated with amygdala cue reactivity in patients
with low depression scores. The study is the ﬁrst ‘imaging
epigenetics’ study in addiction, which, beyond traditional genetic
imaging, may provide further mechanistic insight into causal
pathways of gene–environment interactions and their effect on
brain function.49,50
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